Roche has found redemption in a precision medicine approach following an earlier Tecentriq trial flop in a broader bladder ...

PD-1 inhibitors are projected to dominate future drug sales. Immuno-oncology therapies, particularly the PD-(L)1 class, have revolutionized cancer ca ...

Bladder cancer patients who run out of options often face a grim choice: life-altering surgery to remove the bladder, or living with a disease that might kill them if it spreads to the rest of the ...

Stage-4 cancer patients are living longer, challenging the idea of what it means to have and survive cancer. “The science just needs to stay a step ahead of me” ...

Natera (NTRA) announced positive topline results from the randomized, phase III IMvigor011 clinical trial in muscle-invasive bladder cancer. The ...